The lack of a big picture in tuberculosis: The clinical point of view, the problems of experimental modeling and immunomodulation. The factors we should consider when designing novel treatment strategies

Frontiers in Microbiology

Volumn 5, Issue FEB, 2014, Pages

  Vilaplana, Cristina ^a   Cardona, Pere Joan ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Experimental models; Inflammation; Kramnik model; Liquefaction; M. tuberculosis; Tuberculosis; Tuberculosis disease

Indexed keywords

MOXIFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT;

DYNAMICS; EXPERIMENTAL MODEL; GUINEA PIG; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MACROPHAGE; NEUTROPHIL; NONHUMAN; PATHOLOGY; REVIEW; TUBERCULOSIS;

EID: 84897602653     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2014.00055     Document Type: Review

References (75)

1. Ameni, G., Vordermeier, M., Aseffa, A., Young, D. B., and Hewinson, R. G. (2010). Field evaluation of the efficacy of Mycobacterium bovis bacillus Calmette-Guerin against bovine tuberculosis in neonatal calves in Ethiopia. Clin. Vaccine Immunol. 17, 1533-1538. doi: 10.1128/CVI.00222-10
2. Andersen, P., and Doherty, T. (2005). The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3, 656-662. doi: 10.1038/nrmicro1211
3. Axelrod, S., Oschkinat, H., Enders, J., Schlegel, B., Brinkmann, V., Kaufmann, S. H., et al. (2008). Delay of phagosome maturation by a mycobacterial lipid is reversed by nitric oxide. Cell. Microbiol. 10, 1530-1545. doi: 10.1111/j.1462-5822.2008.01147.x
4. Balcells, M. E., Thomas, S. L., Godfrey-Faussett, P., and Grant, A. D. (2006). Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg. Infect. Dis. 12, 744-751. doi: 10.3201/eid1205.050681
5. Barry, C. E. 3rd. Boshoff, H. I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., et al. (2009). The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7, 845-855. doi: 10.1038/nrmicro2236
6. Berry, M. P., Graham, C. M., McNab, F. W., Xu, Z., Bloch, S. A., Oni, T., et al. (2010). An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973-977. doi: 10.1038/nature09247
7. Brennan, P. (2003). Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb.) 83, 91-97. doi: 10.1016/S1472-9792(02)00089-6
8. Buddle, B. M., Skinner, M. A., Wedlock, D. N., de Lisle, G. W., Vordermeier, H. M., Glyn Hewinson, R., et al. (2005). Cattle as a model for development of vaccines against human tuberculosis. Tuberculosis (Edinb.) 85, 19-24. doi: 10.1016/j.tube.2004.09.003
9. Caceres, N., Llopis, I., Marzo, E., Prats, C., Vilaplana, C., de Viedma, D. G., et al. (2012). Low dose aerosol fitness at the innate phase of murine infection better predicts virulence amongst clinical strains of Mycobacterium tuberculosis. PLoS ONE 7:e29010. doi: 10.1371/journal.pone.0029010
10. Canetti, G. (1955). The Tubercle Bacillus in the Pulmonary Lesion of Man. Histobacteriology and its Bearing on the Therapy of Pulmonary Tuberculosis. New York, NY: Springer Publishing Company, Inc.
11. Capuano, S. R., Croix, D., Pawar, S., Zinovik, A., Myers, A., Lin, P. L., et al. (2003). Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human, M. tuberculosis infection. Infect. Immun. 71, 5831-5844. doi: 10.1128/IAI.71.10.5831-5844.2003
12. Cardona, P., Gordillo, S., Amat, I., Díaz, J., Lonca, J., Vilaplana, C., et al. (2003). Catalase-peroxidase activity has no influence on virulence in a murine model of tuberculosis. Tuberculosis (Edinb.) 83, 351-359. doi: 10.1016/S1472-9792(03)00056-8
13. Cardona, P. J. (2006). RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb.) 86, 273-289. doi: 10.1016/j.tube.2006.01.024
14. Cardona, P. J. (2009). A dynamic reinfection hypothesis of latent tuberculosis infection. Infection 37, 80-86. doi: 10.1007/s15010-008-8087-y
15. Cardona, P. J. (2010). Revisiting the natural history of tuberculosis. The inclusion of constant reinfection, host tolerance, and damage-response frameworks leads to a better understanding of latent infection and its evolution towards active disease. Arch. Immunol. Ther. Exp. (Warsz) 58, 7-14. doi: 10.1007/s00005-009-0062-5
16. Cardona, P. J. (2011). A spotlight on liquefaction: evidence from clinical settings and experimental models in tuberculosis. Clin. Dev. Immunol. 2011, 868246. doi: 10.1155/2011/868246
17. Cardona, P. J., Cooper, A., Luquin, M., Ariza, A., Filipo, F., Orme, I. M., et al. (1999). The intravenous model of murine tuberculosis is less pathogenic than the aerogenic model owing to a more rapid induction of systemic immunity. Scand. J. Immunol. 49, 362-366. doi: 10.1046/j.1365-3083.1999.00522.x
18. Cardona, P. J., and Ivanyi, J. (2011). The secret trumps, impelling the pathogenicity of tubercle bacilli. Enferm. Infecc. Microbiol. Clin. 29(Suppl. 1), 14-19. doi: 10.1016/S0213-005X(11)70013-1
19. Coma, G., Pena, R., Blanco, J., Rosell, A., Borras, F. E., Esté, J. A., et al. (2006). Treatment of monocytes with interleukin (IL)-12 plus IL-18 stimulates survival, differentiation and the production of CXC chemokine ligands (CXCL)8, CXCL9 and CXCL10. Clin. Exp. Immunol. 145, 535-544. doi: 10.1111/j.1365-2249.2006.03145.x
20. Comas, I., Borrell, S., Roetzer, A., Rose, G., Malla, B., Kato-Maeda, M., et al. (2012). Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 44, 106-110. doi: 10.1038/ng.1038
21. Comstock, G. (1999). How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int. J. Tuberc. Lung Dis. 3, 847-850.
22. Converse, P., Dannenberg, A. J., Estep, J., Sugisaki, K., Abe, Y., Schofield, B. H., et al. (1996). Cavitary tuberculosis produced in rabbits by aerosolized virulent tubercle bacilli. Infect. Immun. 64, 4776-4787.
23. Cooper, A. M. (2009). Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 27, 393-422. doi: 10.1146/annurev.immunol.021908.132703
24. Cox, H. S., Morrow, M., and Deutschmann, P. W. (2008). Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ 336, 484-487. doi: 10.1136/bmj.39463.640787.BE
25. Cox, R. (2004). Quantitative relationships for specific growth rates and macromolecular compositions of Mycobacterium tuberculosis, Streptomyces coelicolor A3(2) and Escherichia coli B/r: an integrative theoretical approach. Microbiology 150, 1413-1426. doi: 10.1099/mic.0.26560-0
26. Dannenberg, A. M. J. (2006). Pathogenesis of Human Pulmonary Tuberculosis. Insights from the Rabbit Model. Washington, DC: ASM Press.
27. D'Avila, H., Roque, N. R., Cardoso, R. M., Castro-Faria-Neto, H. C., Melo, R. C., and Bozza, P. T. (2008). Neutrophils recruited to the site of Mycobacterium bovis BCG infection undergo apoptosis and modulate lipid body biogenesis and prostaglandin E production by macrophages. Cell. Microbiol. 10, 2589-2604. doi: 10.1111/j.1462-5822.2008.01233.x
28. de Val Perez, B., Lopez-Soria, S., Nofrarias, M., Martin, M., Vordermeier, H. M., Villarreal-Ramos, B., et al. (2011). Experimental model of tuberculosis in the domestic goat after endobronchial infection with Mycobacterium caprae. Clin. Vaccine Immunol. 18, 1872-1881. doi: 10.1128/CVI.05323-11
29. Dhar, N., and McKinney, J. D. (2010). Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice. Proc. Natl. Acad. Sci. U.S.A. 107, 12275-12280. doi: 10.1073/pnas.1003219107
30. Domingo, M., Gil, O., Serrano, E., Guirado, E., Nofrarias, M., Grassa, M., et al. (2009). Effectiveness and safety of a treatment regimen based on isoniazid plus vaccination with Mycobacterium tuberculosis cells' fragments: field-study with naturally Mycobacterium caprae-infected goats. Scand. J. Immunol. 69, 500-507. doi: 10.1111/j.1365-3083.2009.02251.x
31. Egen, J., Rothfuchs, A., Feng, C., Winter, N., Sher, A., and Germain, R. N. (2008). Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. Immunity 28, 271-284. doi: 10.1016/j.immuni.2007.12.010
32. Farinacci, M., Weber, S., and Kaufmann, S. H. (2012). The recombinant tuberculosis vaccine rBCG DeltaureC::hly(+) induces apoptotic vesicles for improved priming of CD4(+) and CD8(+) T cells. Vaccine 30, 7608-7614. doi: 10.1016/j.vaccine.2012.10.031
33. Flynn, J. L., and Chan, J. (2001). Immunology of tuberculosis. Annu. Rev. Immunol. 19, 93-129. doi: 10.1146/annurev.immunol.19.1.93
34. Fraser, R. S. (2005). "Histology and gross anatomy of the respiratory tract," in Physiologic Basis of Respiratory Disease, eds Q. Hamid, J. Shannon and J. Martin (Hamilton, ON: B.C. Decker inc), 1-14.
35. Gil, O., Diaz, I., Vilaplana, C., Tapia, G., Diaz, J., Fort, M., et al. (2010). Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs. PLoS ONE 5:e10030. doi: 10.1371/journal.pone.0010030
36. Gil, O., Guirado, E., Gordillo, S., Diaz, J., Tapia, G., Vilaplana, C., et al. (2006). Intragranulomatous necrosis in lungs of mice infected by aerosol with Mycobacterium tuberculosis is related to bacterial load rather than to any one cytokine or T cell type. Microbes Infect. 8, 628-636. doi: 10.1016/j.micinf.2005.08.014
37. Glenny, R. W. (2009). Determinants of regional ventilation and blood flow in the lung. Intensive Care Med. 35, 1833-1842. doi: 10.1007/s00134-009-1649-3
38. Gomez, J. E., and McKinney, J. D. (2004). M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb.) 84, 29-44. doi: 10.1016/j.tube.2003.08.003
39. Gonzalez-Avila, G., Sandoval, C., Herrera, M. T., Ruiz, V., Sommer, B., Sada, E., et al. (2009). Mycobacterium tuberculosis effects on fibroblast collagen metabolism. Respiration 77, 195-202. doi: 10.1159/000163064
40. Grosset, J. (1980). Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin. Chest Med. 1, 231-241.
41. Grosset, J. (2003). Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob. Agents Chemother. 47, 833-836. doi: 10.1128/AAC.47.3.833-836.2003
42. Guirado, E., Amat, I., Gil, O., Diaz, J., Arcos, V., Caceres, N., et al. (2006). Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes Infect. 8, 1252-1259. doi: 10.1016/j.micinf.2005.12.004
43. Hamraoui, E. (2006). [The anatomical-clinical conceptualisation of pulmonary tuberculosis in the work of Laennec]. Can. Bull. Med. Hist. 23, 499-539.
44. Hernandez-Pando, R., Jeyanathan, M., Mengistu, G., Aguilar, D., Orozco, H., Harboe, M., et al. (2000). Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 356, 2133-2138. doi: 10.1016/S0140-6736(00)03493-0
45. Ivanyi, J., and Zumla, A. (2013). Nonsteroidal antiinflammatory drugs for adjunctive tuberculosis treatment. J. Infect. Dis. 208, 185-188. doi: 10.1093/infdis/jit153
46. Jawahar, M. S., Banurekha, V. V., Paramasivan, C. N., Rahman, F., Ramachandran, R., Venkatesan, P., et al. (2013). Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS ONE 8:e67030. doi: 10.1371/journal.pone.0067030
47. Jung, Y., Ryan, L., LaCourse, R., and North, R. (2005). Properties and protective value of the secondary versus primary T helper type 1 response to airborne Mycobacterium tuberculosis infection in mice. J. Exp. Med. 201, 1915-1924. doi: 10.1084/jem.20050265
48. Kapina, M. A., Rubakova, E. I., Majorov, K. B., Logunova, N. N., and Apt, A. S. (2013). Capacity of lung stroma to educate dendritic cells inhibiting mycobacteria-specific T-cell response depends upon genetic susceptibility to tuberculosis. PLoS ONE 8:e72773. doi: 10.1371/journal.pone.0072773
49. Korbel, D., Schneider, B., and Schaible, U. (2008). Innate immunity in tuberculosis: myths and truth. Microbes Infect. 10, 995-1004. doi: 10.1016/j.micinf.2008.07.039
50. Langermans, J., Andersen, P., van Soolingen, D., Vervenne, R., Frost, P., van der Laan, T., et al. (2001). Divergent effect of bacillus Calmette-Guérin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proc. Natl. Acad. Sci. U.S.A. 98, 11497-11502. doi: 10.1073/pnas.201404898
51. Lawn, S. D., Meintjes, G., McIlleron, H., Harries, A. D., and Wood, R. (2013). Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review. BMC Med. 11:253. doi: 10.1186/1741-7015-11-253
52. Lecoeur, H. F., Truffot-Pernot, C., and Grosset, J. H. (1989). Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am. Rev. Respir. Dis. 140, 1189-1193. doi: 10.1164/ajrccm/140.5.1189
53. Li, Q., Li, J., Tian, J., Zhu, B., Zhang, Y., Yang, K., et al. (2012). IL-17 and IFN-gamma production in peripheral blood following BCG vaccination and Mycobacterium tuberculosis infection in human. Eur. Rev. Med. Pharmacol. Sci. 16, 2029-2036.
54. Long, E. R., and Faust, R. (1941). The spread of tubercle bacilli by sputum, blood and lymph in pulmonary tuberculosis. Am. J. Pathol. 17, 697-707.
55. Lowe, D. M., Redford, P. S., Wilkinson, R. J., O'Garra, A., and Martineau, A. R. (2012). Neutrophils in tuberculosis: friend or foe? Trends Immunol. 33, 14-25. doi: 10.1016/j.it.2011.10.003
56. Lurie, M. B., Zappasodi, P., and Tickner, C. (1955). On the nature of genetic resistance to tuberculosis in the light of the host-parasite relationships in natively resistant and susceptible rabbits. Am. Rev. Tuberc. 72, 297-329.
57. Martineau, A., Newton, S., Wilkinson, K., Kampmann, B., Hall, B., Nawroly, N., et al. (2007). Neutrophil-mediated innate immune resistance to mycobacteria. J. Clin. Invest. 117, 1988-1994. doi: 10.1172/JCI31097
58. Marzo, E., Vilaplana, C., Tapia, G., Diaz, J., Garcia, V., and Cardona, P. J. (2013). Damaging role of neutrophilic infiltration in a mouse model of progressive tuberculosis. Tuberculosis (Edinb.), 94, 55-64. doi: 10.1016/j.tube.2013.09.004
59. Grenville-Mathers, R. (1947). Cavitation in pulmonary tuberculosis. Tubercle 28, 139-143. doi: 10.1016/S0041-3879(47)80017-0
60. McMurray, D., Collins, F., Dannenberg, A. J., and Smith, D. (1996). Pathogenesis of experimental tuberculosis in animal models. Curr. Top. Microbiol. Immunol. 215, 157-179. doi: 10.1007/978-3-642-80166-2_7
61. Medlar, E. M., and Sasano, K. T. (1936). A study of pathology of experimental tuberculosis. Am. Rev. Tuberc. 34, 456.
62. Mochizuki, M. (1990). Blood-gas transfer of O2 and CO2 in the lungs: new models, measurements and conclusions. Adv. Exp. Med. Biol. 277, 587-592. doi: 10.1007/978-1-4684-8181-5_66
63. Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., Williams, K., Rosenthal, I., O'Brien, R. J., et al. (2004). Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med. 170, 1131-1134. doi: 10.1164/rccm.200407-885OC
64. Orme, I. M. (2005). Mouse and guinea pig models for testing new tuberculosis vaccines. Tuberculosis (Edinb.) 85, 13-17. doi: 10.1016/j.tube.2004.08.001
65. Rastogi, N., and David, H. L. (1993). Mode of action of antituberculous drugs and mechanisms of drug resistance in Mycobacterium tuberculosis. Res. Microbiol. 144, 133-143. doi: 10.1016/0923-2508(93)90028-Z
66. Rey-Jurado, E., Tudo, G., Borrell, S., Alcaide, F., Coll, P., Español, M., et al. (2011). Impaired fitness of Mycobacterium tuberculosis resistant isolates in a cell culture model of murine macrophages. J. Antimicrob. Chemother. 66, 2277-2280. doi: 10.1093/jac/dkr288
67. Rieder, H. L., Cauthen, G. M., Comstock, G. W., and Snider, D. E. Jr. (1989). Epidemiology of tuberculosis in the United States. Epidemiol. Rev. 11, 79-98.
68. Tan, B. H., Meinken, C., Bastian, M., Bruns, H., Legaspi, A., Ochoa, M. T., et al. (2006). Macrophages acquire neutrophil granules for antimicrobial activity against intracellular pathogens. J. Immunol. 177, 1864-1871.
69. Tobin, D. M., and Ramakrishnan, L. (2008). Comparative pathogenesis of Mycobacterium marinum and Mycobacterium tuberculosis. Cell. Microbiol. 10, 1027-1039. doi: 10.1111/j.1462-5822.2008.01133.x
70. Uhlin, M., Andersson, J., Zumla, A., and Maeurer, M. (2012). Adjunct immunotherapies for tuberculosis. J. Infect. Dis. 205(Suppl. 2), S325-S334. doi: 10.1093/infdis/jis197
71. Verreck, F., Vervenne, R., Kondova, I., van Kralingen, K., Remarque, E., Braskamp, G., et al. (2009). MVA.85A boosting of BCG and an attenuated, phoP deficient, M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS ONE 4:e5264. doi: 10.1371/journal.pone.0005264
72. Vilaplana, C., Marzo, E., Tapia, G., Diaz, J., Garcia, V., and Cardona, P. J. (2013). Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J. Infect. Dis. 208, 199-202. doi: 10.1093/infdis/jit152
73. Wayne, L. (1994). Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. Clin. Microbiol. Infect. Dis. 13, 908-914. doi: 10.1007/BF02111491
74. Yan, B., Kirby, A., Shebzukhov, Y., Daly, M., and Kramnik, I. (2006). Genetic architecture of tuberculosis resistance in a mouse model of infection. Genes Immun. 7, 201-210. doi: 10.1038/sj.gene.6364288
75. Zenner, D., Southern, J., van Hest, R., DeVries, G., Stagg, H. R., Antoine, D., et al. (2013). Active case finding for tuberculosis among high-risk groups in low-incidence countries. Int. J. Tuberc. Lung Dis. 17, 573-582. doi: 10.5588/ijtld.12.0920